APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch

Status: Recruiting

Location: See location...

Study Type: Observational

SUMMARY

APOLLO 11 main aim is to build a strong Italian long-lasting lung cancer network (in around 48 Italian centres) on real world data and translational research by creating a decentralized long-term national database (settle locally in each centre) and a virtual multilevel biobank in each centre. Besides, APOLLO 11 will take advantage of the translational research joint effort with the credo unity is strength.

Eligibility

Participation Requirements

Sex: All

Minimum Age: 18

Healthy Volunteers: f

View:

• Provision of signed and dated written informed consent, when applicable, by the patient or legally acceptable representative prior to any mandatory study-specific procedures, sampling, and analyses;

• Patients must be ≥18 years of age at the time of signing the informed consent;

• Histologically or cytologically confirmed lung cancer (NSCLC or SCLC) at any stage (I-IV) candidate to receive or already treated with innovative therapies (ICIs, target therapies and next generation therapies).

Locations

Other Locations

Italy

Fondazione IRCCS Istituto Nazionale dei Tumori

RECRUITING

Milan

Contact Information

Primary

Arsela Prelaj, M.D.

arsela.prelaj@istitutotumori.mi.it

+390223903647

Time Frame

Start Date: 2022-10-01

Estimated Completion Date: 2032-10-01

Participants

Target number of participants: 1200

Treatments

Retrospective Cohort

About 1000 patients with NSCLC pre-treated with innovative therapy (e.g. immunotherapy, targeted therapy) will be included.

Prospective Cohort

About 200 patients with NSCLC planned to start an innovative therapy (e.g. immunotherapy, targeted therapy) will be included.

Related Therapeutic Areas

Lung Cancer

Lung Adenocarcinoma

Sponsors

Collaborators: Azienda Ospedaliera Sant'Andrea, Istituti Ospitalieri di Cremona, Insieme per i Pazienti di Oncologia Polmonare Onlus (IPOP), Azienda Ospedaliera S. Maria della Misericordia, Fondazione IRCCS Policlinico San Matteo di Pavia, Politecnico di Milano, University of Campania Luigi Vanvitelli, Azienda Ospedaliero Universitaria, Santa Maria della Misericordia di Udine, Italy, Ospedale Policlinico San Martino, Istituto Clinico Humanitas, ASST Grande Ospedale Metropolitano Niguarda, Azienda Ospedaliera dei Colli, Azienda Unità Sanitaria Locale della Romagna, IRCCS Sacro Cuore Don Calabria di Negrar, Azienda Ospedaliero, Universitaria Ospedali Riuniti

Leads: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

View All

APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch

Similar Clinical Trials

A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors

A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors

Evaluation of an Ultrasensitive Next Generation Sequencing Method for the Detection of EGFR Gene Mutations in the Plasma of Patients With Lung Cancer

Evaluation of an Ultrasensitive Next Generation Sequencing Method for the Detection of EGFR Gene Mutations in the Plasma of Patients With Lung Cancer

A Phase I/Ⅱ, First-in-Human Study of XNW27011 in Patients with Locally Advanced And/or Metastatic Solid Tumors

A Phase I/Ⅱ, First-in-Human Study of XNW27011 in Patients with Locally Advanced And/or Metastatic Solid Tumors